In 1982, tissue-type plasminogen activator was first produced by recombinant DNA techniques at Genentech. Recombinant tPA made it possible to manufacture a clot-dissolving protein for emergency treatment. It later became important in selected cases of myocardial infarction, pulmonary embolism and ischaemic stroke.

The production of recombinant tissue plasminogen activator in 1982 marked a new era in biotechnology, allowing for the replication and redirection of the body's own substances. This innovation infused artistic images of time-critical rescue with urgency, influencing poetry that explores themes of healing and restoration following trauma.